Skip to main content
Quest Diagnostics Home

Hypercoagulable State Associated With COVID-19 Infection

Date: Thursday, Nov 12, 2020

Description:

  • Identify key coagulation markers that are associated with increasedmortality in COVID-19 infected patients
  • Distinguish COVID-19 hypercoagulability from other hypercoagulable states
  • Understand key laboratory issues associated with thrombophilia testing and anticoagulant monitoring in patients with COVID-19 infection

Authors:

Racke, Frederick K., MD, PhD.
Medical Director, Hematology/Oncology and Coagulation,
Nichols Institute
Quest Diagnostics
San Juan Capistrano, CA

Wong, Edward C. C., MD
Medical Director, Quest Diagnostics; Adj Assoc Professor, George Washington School of Medicine and Health Sciences; Clinical Consultant, Children’s National Hospital 

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2023 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.